ranolazine has been researched along with mexiletine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Belardinelli, L; Corkey, B; Desai, MC; Dhalla, AK; El-Bizri, N; Elzein, E; Graupe, M; Guerrero, J; Hirakawa, R; Hu, L; Jiang, H; Kahlig, K; Kalla, R; Kobayashi, T; Koltun, DO; Lepist, EI; Li, CH; Li, X; Li, XJ; Liu, G; Lu, Y; Martinez, R; Mollova, N; Murray, B; Notte, GT; Osier, M; Parkhill, EQ; Perry, J; Perry, T; Rajamani, S; Rhodes, G; Saunders, O; Soohoo, D; Strickley, R; Venkataramani, C; Wang, WQ; Xie, C; Zablocki, JA | 1 |
| Bichler, P; Chang, E; Cohen, CJ; de Boer, G; Dean, R; Dehnhardt, CM; Empfield, JR; Goodchild, SJ; Hussainkhel, A; Jia, Q; Johnson, JP; Khakh, K; Kwan, R; Lin, S; Lindgren, A; Mezeyova, J; Sojo, L; Sun, S; Xie, Z; Zenova, AY | 1 |
| Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP | 1 |
| Al-Khatib, SM; Allen LaPointe, NM; Curtis, LH; Hammill, BG; Mi, X; Pokorney, SD | 1 |
| King, T; Mann, N; Murphy, R | 1 |
| Bergau, D; Bystricky, W; Carter, D; Gintant, G; Kamradt, K; Maier, C; Welsh, P | 1 |
| Arnold, WD; Barohn, RJ; Cannon, SC; Fontaine, B; Griggs, RC; Hanna, MG; LoRusso, S; Matthews, E; Meola, G; Sansone, VA; Statland, JM; Stunnenberg, BC; Trivedi, JR; van Engelen, BGM; Vicart, S | 1 |
| Li, SY; Lv, TT; Yang, Y; Zhang, P | 1 |
| Hayashi, S; Kanda, Y; Ono, A; Satsuka, A; Yanagida, S | 1 |
4 review(s) available for ranolazine and mexiletine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review of primary and secondary erythromelalgia.
Topics: Capsaicin; Erythromelalgia; Humans; Mass Screening; Mexiletine; Myeloproliferative Disorders; NAV1.7 Voltage-Gated Sodium Channel; Ranolazine; Sensory System Agents; Sodium Channel Blockers; Sympathectomy | 2019 |
Guidelines on clinical presentation and management of nondystrophic myotonias.
Topics: Acetazolamide; Age of Onset; Carbonic Anhydrase Inhibitors; Chloride Channels; Electrodiagnosis; Electromyography; Fatigue; Genetic Testing; Humans; Lamotrigine; Mexiletine; Muscle Weakness; Muscle, Skeletal; Myalgia; Myotonia Congenita; Myotonic Disorders; NAV1.4 Voltage-Gated Sodium Channel; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Voltage-Gated Sodium Channel Blockers | 2020 |
Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Flecainide; Humans; Long QT Syndrome; Mexiletine; Ranolazine; Sodium Channel Blockers | 2021 |
1 trial(s) available for ranolazine and mexiletine
| Article | Year |
|---|---|
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization.
Topics: Action Potentials; Adult; Databases, Factual; Double-Blind Method; Electrocardiography; Female; Heart; Humans; Lidocaine; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil; Young Adult | 2019 |
5 other study(ies) available for ranolazine and mexiletine
| Article | Year |
|---|---|
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
Topics: | 2016 |
Identification of aryl sulfonamides as novel and potent inhibitors of Na
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; NAV1.5 Voltage-Gated Sodium Channel; Structure-Activity Relationship; Sulfonamides | 2021 |
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Defibrillators, Implantable; Drug Therapy, Combination; Electric Countershock; Electrocardiography; Female; Humans; Hypoglycemia; Lidocaine; Male; Mexiletine; Middle Aged; Myocardial Ischemia; Piperazines; Ranolazine; Sotalol; Stroke Volume; Tachycardia, Ventricular; Treatment Outcome | 2011 |
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Countershock; Female; Humans; Logistic Models; Male; Medicare Part D; Mexiletine; Ranolazine; Sodium Channel Blockers; Sotalol; Tachycardia, Ventricular; United States | 2017 |
Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes.
Topics: Aspirin; Bepridil; DNA-Binding Proteins; Humans; Induced Pluripotent Stem Cells; Mexiletine; Myocytes, Cardiac; Ranolazine; Risk Assessment | 2022 |